Table 2 Distribution of genotypic and allelic frequencies of MAOA uVNTR in the drug response classes assessed by Chi-test analysis
From: Genetic polymorphisms related to efficacy and overuse of triptans in chronic migraine
MAOA uVNTR genotypea | Therapy response grade | |||||||
|---|---|---|---|---|---|---|---|---|
0–25% (class 1) | 25–50% (class 2) | 50–75% (class 3) | 75–100% (class 4) | |||||
Obs. | Exp. | Obs. | Exp. | Obs. | Exp. | Obs. | Exp. | |
3R3R | 0 | 3.60 | 8 | 3.33 | 1 | 3.87 | 7 | 5.2 |
3R4R | 12 | 11.2 | 10 | 10.4 | 10 | 12.1 | 18 | 16.2 |
4R4R | 15 | 12.2 | 7 | 11.2 | 18 | 13.1 | 14 | 17.6 |
MAOA uVNTR allelesb | 0–25% (class 1) | 25–50% (class 2) | 50–75% (class 3) | 75–100% (class 4) | ||||
Obs. | Exp. | Obs. | Exp. | Obs. | Exp. | Obs. | Exp. | |
3R | 13 | 18.7 | 26 | 17.0 | 12 | 20.1 | 32 | 27.2 |
4R | 42 | 36.3 | 24 | 33.0 | 47 | 38.9 | 48 | 52.8 |